⚕ GalenOps field
←

SITE001-0157

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2022-08-27

AEs
6
Serious
1
Dropout signal
–

Adverse events

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-10-29 (study day 43); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-05 (study day 50); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-05-19 (study day 245); relationship: Y

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-22 (study day 340); relationship: N

severe serious assessed

Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-12-03 (study day 443); relationship: not assessed; serious criteria: hospitalization

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-12-16 (study day 456); relationship: not assessed

Data queries

No data queries.